Últimas noticias sobre Abbott Laboratories (NYSE:ABT) Bolsa

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

ABBOTT LABORATORIES ORD

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $122 to $129.

News

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $129

As Columbus Day approaches, investors and market participants are preparing for a unique trading environment. This U.S. holiday, observed on Monday, October 14, 2024, will see a mix of open and closed financial markets, impacting trading activities.
Columbus Day, a federal holiday commemorating the 1492 landing of Christopher Columbus in North America, will see the New York Stock Exchange and the Nasdaq Stock Market operating as usually. Over-the-counter (OTC) markets will also remain open, while bond markets will be closed. The U.S. Postal Service and the Federal Reserve will not operate, and many banks will follow suit. 
In some states, the day is also recognized as Indigenous People&#8217;s Day, celebrating the resilience of Indigenous communities.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41299648/bitcoin-ethereum-dogecoin-see-friday-gains-but-trader-warns-59-000-must-hold-no-major-move?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin See Friday Gains, But Trader Warns &#8216;$59,000 Must Hold, No Major Moves Expecte</a>
Internationally, trading will continue as usual in most markets, except for the Toronto Stock Exchange, which will close in observance of Canada&#8217;s Thanksgiving Day. 
Investors should brace for a busy week with earnings reports from major companies such as UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), and Taiwan Semiconductor Manufacturing Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>). Additionally, key economic data releases, including jobless claims, retail sales, and housing starts, will provide insights into the current state of the economy.
Price Action: On Monday during pre-market hours, at the time of writing, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was trading slight higher, around 0.22% while Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up by 0.32%, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41288392/justin-biebers-2024-crypto-returns-discover-how-much-the-pop-icon-made-on-his-ethereum-inv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Justin Bieber&#8217;s 2024 Crypto Returns – Discover How Much The Pop Icon Made On His Ethereum Investment!</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Markets

General

Columbus Day: Is Stock Market Open Today?

Biotech

Abbott Advances Pulsed Field Ablation Clinical Studies With Early Enrollment Completion For Volt PFA System And Launches FOCALFLEX Trial For TactiFlex Duo Ablation Catheter; Receives FDA Clearance For Advisor HD Grid X Mapping Catheter And Begins U.S. Commercial Launch

RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $125 to $130.

RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $130

Abbott Laboratories&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) MedTech portfolio is growing at a CAGR (compounded annual growing rate) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946305/abbott-laboratories-attractive-valuation-ranks-it-among-top-large-cap-medtech-compa">of 11%-13%</a>. 
The company&#8217;s non-MedTech operations are expanding by low-to-mid single-digit percentages, according to Oppenheimer.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5909e5c2290fa700012c0333/suraj-kalia">Analyst Suraj Kalia</a> initiated coverage of Abbott Laboratories with an Outperform rating and price target of $130.
The Abbott Laboratories Thesis: The company's MedTech portfolio currently contributes around 45% of total sales of about $42 billion, Kalia said in the initiation note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Abbott's product pipeline boosts confidence in the company's long-term growth, the analyst stated. 
While its various offerings provide "structural advantages for product bundling," the company has also made disciplined MedTech acquisitions, he added.
On the non-MedTech side, Nutrition and Diagnostics sales comps will ease over the next few years, driving revenue growth with margin expansion of 30 to 50 basis points per year in fiscal 2026 and beyond, Kalia further wrote.
Price Action: Shares of Abbott Laboratories had risen by 0.7% to $114.17 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/partner/health-care/24/10/41162090/expanding-continuous-glucose-monitoring-options-how-glucotrack-is-helping-usher-in-the-next-g">Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Initiation

Trading Ideas

Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth

In the current market session, Abbott Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) share price is at $114.38, after a 0.90% increase. Moreover, over the past month, the stock decreased by 2.33%, but in the past year, spiked by 24.15%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1728399623_0_0.png" alt="Past Year Chart" />

<h3>Abbott Laboratories P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 273.66 in the Health Care Equipment &amp; Supplies industry, Abbott Laboratories Inc. has a lower P/E ratio of 35.76. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1728399623_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Abbott Laboratories Inc's Price Over Earnings

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5909e5c2290fa700012c0333/suraj-kalia">Oppenheimer analyst Suraj Kalia</a> initiated coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with an Outperform rating and announced a price target of $130. Abbott shares gained 0.6% to close at $113.36 on Monday. <a href="https://www.benzinga.com/quote/abt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Eva Fortea Verdejo initiated coverage on Arcus Biosciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) with an Overweight rating and announced a price target of $29. Arcus Biosciences shares gained 3.9% to close at $17.30 on Monday. <a href="https://www.benzinga.com/quote/RCUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586cf168351b9b0001a30552/charles-minervino">Susquehanna analyst Charles Minervino</a> initiated coverage on Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Positive rating and announced a price target of $120. Howmet Aerospace shares gained 0.8% to close at $102.83 on Monday. <a href="https://www.benzinga.com/quote/HWM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Judah Frommer initiated coverage on Bicara Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with an Overweight rating and announced a price target of $35. Bicara Therapeutics shares fell 2.8% to close at $24.45 on Monday. <a href="https://www.benzinga.com/quote/BCAX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Hovde Group initiated coverage on First National Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FXNC#NASDAQ">FXNC</a>) with an Outperform rating and announced a price target of $22. First National shares gained 0.9% to close at $18.37 on Monday. <a href="https://www.benzinga.com/quote/FXNC/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08090124/image-51-1024x504.png" alt="" class="wp-image-585542" style="width:646px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08090124/image-51-1024x504.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08090124/image-51-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08090124/image-51-768x378.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08090124/image-51.png 1347w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41221716/dow-dips-around-400-points-as-treasury-yields-top-4-investor-optimism-declines-but-fear-index-remai">Dow Dips Around 400 Points As Treasury Yields Top 4%: Investor Optimism Declines, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

BCAX

FXNC

RCUS

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Oppenheimer analyst Suraj Kalia initiates coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform rating and announces Price Target of $130.

Oppenheimer Initiates Coverage On Abbott Laboratories with Outperform Rating, Announces Price Target of $130

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 4.05% since its last report. The company recently reported that it has 13.36 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728331215_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.42%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Abbott Laboratories?

<a href="https://www.who.int/news/item/03-10-2024-who-approves-first-mpox-diagnostic-test-for-emergency-use--boosting-global-access">https://www.who.int/news/item/03-10-2024-who-approves-first-mpox-diagnostic-test-for-emergency-use--boosting-global-access</a>
The World Health Organization (WHO) has listed the first mpox in vitro diagnostic (IVD) under its Emergency Use Listing (EUL) procedure, an important step in improving global access to mpox testing. The approval for emergency use of <a href="https://extranet.who.int/prequal/sites/default/files/document_files/eul-mpxv_list-of-mpxv-ivds.pdf">the Alinity m MPXV assay, manufactured by Abbott Molecular Inc.</a>, will be pivotal in expanding diagnostic capacity in countries facing mpox outbreaks, where the need for quick and accurate testing has risen sharply. Early diagnosis of mpox enables timely treatment and care, and control of the virus.
Limited testing capacity and delays in confirming mpox cases persist in Africa, contributing to the continued spread of the virus. In 2024, over 30 000 suspected cases have been reported across the region, with the highest numbers in the Democratic Republic of the Congo, Burundi, and Nigeria. In the Democratic Republic of the Congo, only 37% of suspected cases have been tested this year.
The presence of the monkeypox virus is confirmed by nucleic acid amplification testing (NAAT), such as real-time or conventional polymerase chain reaction (PCR), as stated in the <a href="https://iris.who.int/bitstream/handle/10665/376952/WHO-MPX-Laboratory-2024.1-eng.pdf?sequence=1">WHO Interim Guidance on Diagnostic testing for the monkeypox virus (MPXV)</a>. And the recommended specimen type for diagnostic confirmation of monkeypox virus (MPXV) infection in suspected cases is lesion material.
The Alinity m MPXV assay is a real-time PCR test that enables detection of monkeypox virus (clade I/II) DNA from human skin lesion swabs. It is specifically designed for use by trained clinical laboratory personnel who are proficient in PCR techniques and IVD procedures. By detecting DNA from pustular or vesicular rash samples, laboratory and health workers can confirm suspected mpox cases efficiently and effectively.
"This first mpox diagnostic test listed under the Emergency Use Listing procedure represents a significant milestone in expanding testing availability in affected countries," said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products. "Increasing access to quality-assured medical products is central to our efforts in assisting countries to contain the spread of the virus and protect their people, especially in underserved regions."
The EUL process accelerates the availability of life-saving medical products, such as vaccines, tests and treatments, in the context of a Public Health Emergency of International Concern (PHEIC). On 28 August 2024, WHO called on mpox IVDs manufacturers <a href="https://extranet.who.int/prequal/news/invitation-manufacturers-vitro-diagnostics-monkeypox-virus-nucleic-acid-detection-submit">to submit an expression of interest for EUL</a>, recognizing the urgent need to bolster global testing capacities as the virus continued to spread. The EUL process assesses the quality, safety, and performance of essential health products, such as diagnostic tests, to guide procurement agencies and WHO Member States in making informed decisions for time-limited emergency procurement.
So far, WHO has received three additional submissions for EUL evaluation, and discussions are ongoing with other manufacturers of mpox IVDs to ensure a wider range of quality-assured diagnostic options. This will support countries which have not approved the medical products through their own approval processes to procure the critically needed tests through UN agencies and other procurement partners.
The EUL for Alinity m MPXV assay, allowing for its use, will remain valid as long as the PHEIC, justifying the emergency use of mpox in vitro diagnostics, is in effect.
Information on active EUL applications for mpox IVDs can be found on these&nbsp;<a href="https://extranet.who.int/prequal/sites/default/files/document_files/eul-mpxv_status-of-ongoing-applications-1.pdf">WHO webpages</a>.

WHO Approves First Mpox Diagnostic Test For Emergency Use, Boosting Global Access;  The Approval For Emergency Use Of The Alinity M MPXV Assay, Manufactured By Abbott Molecular Inc. - WHO

Evercore ISI Group analyst Vijay Kumar maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $120 to $124.

Evercore ISI Group Maintains Outperform on Abbott Laboratories, Raises Price Target to $124

Across the recent three months, 6 analysts have shared their insights on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $126.83, with a high estimate of $143.00 and a low estimate of $120.00. This current average has increased by 2.95% from the previous average price target of $123.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1727373633_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Abbott Laboratories is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$131.00</td>
<td>-</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Abbott Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Abbott Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Abbott Laboratories's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Get to Know Abbott Laboratories Better</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Breaking Down Abbott Laboratories's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Abbott Laboratories's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 4.0%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Abbott Laboratories's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.55% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Abbott Laboratories's ROE excels beyond industry benchmarks, reaching 3.33%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's ROA excels beyond industry benchmarks, reaching 1.79%. This signifies efficient management of assets and strong financial health.
Debt Management: Abbott Laboratories's debt-to-equity ratio is below the industry average. With a ratio of 0.38, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 6 Analyst Ratings For Abbott Laboratories

Jefferies analyst Raj Denhoy reiterates Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Hold and maintains $120 price target.

Reiteration

Jefferies Reiterates Hold on Abbott Laboratories, Maintains $120 Price Target

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), noting the company as a versatile large-cap with an attractive valuation.
Abbott has a diversified business model with solid distribution across segments (medtech, diagnostics, nutrition, pharmaceuticals) and geography. Medical devices are the company&#8217;s largest business, accounting for around 44% of total sales.
Abbott Laboratories&nbsp;reported second-quarter sales of $10.38 billion, up 4%, almost in line with the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.37 billion</a>.
Organic sales growth for the underlying base business was 9.3%, led by double-digit&nbsp;growth <a href="https://www.benzinga.com/24/07/39839507/abbott-laboratories-q2-earnings-revenue-and-profit-beat-estimates-nudges-up-annual-profit-guidance-o" target="_blank" rel="noreferrer noopener">in medical devices</a>.
Piper Sandler noted that the company struck a solid balance by achieving above-average growth for a large-cap medtech firm, maintaining strong efficiency metrics, and consistently paying dividends to shareholders.
Abbott has positioned itself as a high-single-digit growth company, placing it near the top of the large-cap medtech sector. Its medtech division has consistently contributed to overall growth, with expectations for double-digit expansion from 2024 to 2026.
Analyst Adam C. Maeder initiated coverage with an Overweight rating and a <a href="https://www.benzinga.com/quote/ABT/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $131</a>.
Talking about the valuation, the analyst highlighted that Abbott&#8217;s stock is currently valued at 22.3 times the consensus adjusted EPS estimates for 2025, reflecting a notable discount compared to its large-cap medtech peers.
This discount is partly driven by ongoing necrotizing enterocolitis (NEC) litigation, but the analyst contends that Abbott should still be trading at least on par with its peers, given its strong revenue growth and adjusted EPS outlook.
In July, Abbott stock fell following a U.S. jury&#8217;s ruling that found Abbott&#8217;s formula was responsible for a girl developing a severe bowel disease, leading to a hefty $495 million penalty. This verdict is part of nearly 1,000 lawsuits filed against Abbott Labs, its British rival&nbsp;Reckitt Benckiser Group PLC &#8211; ADR&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RBGLY#OTC">RBGLY</a>), both in U.S.<a href="https://www.benzinga.com/general/biotech/24/07/40006590/abbott-laboratories-tumble-nearly-8-in-pre-market-after-us-jury-charges-495m-penalty-for-disease-" target="_blank" rel="noreferrer noopener"> federal or state courts</a>.
&#8220;We don&#8217;t see much topline risk associated with the litigation, and we believe the Street is already pricing potential damages into the stock,&#8221; the analyst added.
ABT Price Action: Abbott Laboratories stock is down 1.07% at $113.66 at last publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40943923/theratechnologies-faces-potential-supply-disruption-for-its-top-selling-drug-warns-of-revenue-imp" target="_blank" rel="noreferrer noopener">Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays</a>.</li>
</ul>
Photo: Abbott

Large Cap

Health Care

RBGLY

Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e60ff475f2b9b000113c537/adam-maeder">Piper Sandler analyst Adam Maeder</a> initiated coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with an Overweight rating and announced a price target of $131. Abbott shares fell 2.8% to close at $114.88 on Wednesday. <a href="https://www.benzinga.com/quote/ABT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Roth MKM analyst Scott Fortune initiated coverage on Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy rating and announced a price target of $50. Turning Point Brands shares gained 0.9% to close at $39.03 on Wednesday. <a href="https://www.benzinga.com/quote/TPB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>R<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/641c1355c9c7840001d30a8f/james-rollyson">aymond James analyst James Rollyson</a> initiated coverage on Helix Energy Solutions Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) with a Strong Buy rating and announced a price target of $14. Helix Energy shares fell 1.8% to close at $9.84 on Wednesday. <a href="https://www.benzinga.com/quote/HLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital analyst Jonathan Atkin initiated coverage on Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Sector Perform rating and announced a price target of $345. Charter Communications shares gained 0.1% to close at $339.64 on Wednesday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst William Janela initiated coverage on Northern Oil and Gas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) with an Outperform rating and announced a price target of $47. Northern Oil &amp; Gas shares rose 0.3% to close at $36.17 on Wednesday. <a href="https://www.benzinga.com/quote/NOG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-1024x512.png" alt="" class="wp-image-556133" style="width:656px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-1024x512.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-768x384.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154.png 1325w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40925678/fedex-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-an">FedEx Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

CHTR

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Piper Sandler analyst Adam Maeder initiates coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight rating and announces Price Target of $131.

Piper Sandler Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $131

Investors are on edge in the lead-up to the Wednesday Federal Open Market Committee interest rate decision that is expected to deliver the first cut to the federal funds rate <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40921827/fed-decision-is-here-5-things-investors-need-to-know-ahead-of-wednesdays-pivotal-in">in over four years.</a>
The market is divided on the magnitude of the anticipated rate cut. Traders are assigning a 59% probability to a 50-basis-point cut, while a 41% chance is placed on a more modest 25-basis-point reduction. The size of the rate cut is crucial as it could trigger significant market reactions.
Should the Fed opt for a 50-basis-point cut, it may be perceived as an acknowledgment that interest rates are overly restrictive. This could lead to increased expectations for further rate cuts in the coming months, potentially fueling risk sentiment and driving stock prices higher.
Conversely, a 25-basis-point cut might disappoint investors who are betting on a more aggressive measure.
Since the start of 2022, the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has experienced an average move of plus or minus 1.3% during FOMC events, reflecting the market&#8217;s high sensitivity to Fed policy decisions.
Goldman Sachs equity analysts, including John Marshall, analyzed stock movements during the first rate cuts in the previous three Fed easing cycles (Sept. 18, 2007, July 31, 2019 and March 3, 2020).
The data highlights the average moves of several key S&amp;P 500 stocks with liquid options during these periods.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Rank</th>
<th>Name</th>
<th>Absolute Average Move</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Caesars Entertainment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>)</td>
<td>5.9%</td>
</tr>
<tr>
<td>2</td>
<td>Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>5.5%</td>
</tr>
<tr>
<td>3</td>
<td>Capital One Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>)</td>
<td>4.6%</td>
</tr>
<tr>
<td>4</td>
<td>Charles Schwab Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>)</td>
<td>4.6%</td>
</tr>
<tr>
<td>5</td>
<td>Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>)</td>
<td>4.5%</td>
</tr>
<tr>
<td>6</td>
<td>Fortinet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>)</td>
<td>4.3%</td>
</tr>
<tr>
<td>7</td>
<td>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>)</td>
<td>4.2%</td>
</tr>
<tr>
<td>8</td>
<td>American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</td>
<td>3.8%</td>
</tr>
<tr>
<td>9</td>
<td>Newmont Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>3.7%</td>
</tr>
<tr>
<td>10</td>
<td>Deere &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>)</td>
<td>3.6%</td>
</tr>
<tr>
<td>11</td>
<td>BlackRock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>)</td>
<td>3.6%</td>
</tr>
<tr>
<td>12</td>
<td>Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</td>
<td>3.5%</td>
</tr>
<tr>
<td>13</td>
<td>3M Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>)</td>
<td>3.3%</td>
</tr>
<tr>
<td>14</td>
<td>Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</td>
<td>3.2%</td>
</tr>
<tr>
<td>15</td>
<td>JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</td>
<td>3.2%</td>
</tr>
<tr>
<td>16</td>
<td>Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)</td>
<td>3.0%</td>
</tr>
<tr>
<td>17</td>
<td>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</td>
<td>3.0%</td>
</tr>
<tr>
<td>18</td>
<td>Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)</td>
<td>2.9%</td>
</tr>
<tr>
<td>19</td>
<td>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td>2.7%</td>
</tr>
<tr>
<td>20</td>
<td>Verizon Communications Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</td>
<td>2.3%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40908202/10-etfs-investors-secretly-bought-before-the-feds-make-or-break-interest-rate-cal">10 ETFs Investors Secretly Bought Before The Fed&#8217;s Make-Or-Break Interest Rate Call</a></li>
</ul>
Federal Reserve illustration created using artificial intelligence via MidJourney.

Equities

Mid Cap

Broad U.S. Equity ETFs

Econ #s

Federal Reserve

ETFs

FTNT

NVDA

ORCL

SBUX

SCHW

20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates

Thursday, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.
The <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/continuous-glucose-monitoring-cgm-sensor-recall-abbott-diabetes-care-inc-issues-recall-certain" rel="noreferrer noopener">use</a> of the affected product may cause serious adverse health consequences, including severe low blood sugar (hypoglycemia), which can cause central nervous system problems, loss of consciousness, seizures, coma, permanent brain damage, and death.
There have been two reported injuries. There have been no reports of death.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/08/40556465/dexcoms-stelo-device-brings-affordable-continuous-glucose-monitoring-to-type-2-diabetes-patients" rel="noreferrer noopener">Dexcom&#8217;s Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients</a>.
This&nbsp;<a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/what-medical-device-recall" rel="noreferrer noopener">recall</a> involves removing certain devices from where they are used or sold and does not apply to the FreeStyle Libre 3 reader or app.
The FreeStyle Libre 3 Continuous Glucose Monitoring System is intended to monitor glucose levels continuously. It helps people manage diabetes by detecting trends and tracking patterns in glucose levels so treatment can be adjusted as needed. It is indicated for single-patient use and requires a prescription.
In July, Abbott sent all affected customers an Urgent Medical Device Recall recommending discontinuing the use, disposing of any affected sensors, and requesting a replacement.
Concurrently, on Thursday, Abbott&nbsp;announced the U.S. availability of Lingo, the company&#8217;s first continuous glucose monitoring system, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40729936/abbotts-lingo-continuous-glucose-monitor-for-health-and-wellness-now-available-in-the-u-s" rel="noreferrer noopener">without a prescription</a>.
The Lingo system includes a biosensor and a mobile app designed for consumers who want to improve their overall health and wellness.
Lingo is based on Abbott&#8217;s FreeStyle Libre continuous glucose monitoring technology.
Abbott&#8217;s consumer biowearable, Lingo, is available for consumers 18 years and older not on insulin. Lingo tracks glucose in real-time and provides personal insights and coaching to help people build healthy habits, retrain their metabolism, and improve their overall well-being.
Price Action: ABT stock is down 0.82% at $113.46 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40736321/battle-over-compounded-weight-loss-medications-sustainability-and-regulation" target="_blank" rel="noreferrer noopener">Battle Over Compounded Weight-Loss Medications &#8211; Sustainability and Regulation</a>.</li>
</ul>
Photo via Shutterstock

Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock&#39;s price, but are they really important?
Let&#39;s take a look at what these Wall Street heavyweights have to say about Abbott (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Abbott currently has an average brokerage recommendation of 1.57, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 21 brokerage firms. An ABR of 1.57 approximates between Strong Buy and Buy.
Of the 21 recommendations that derive the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.7% and 9.5% of all recommendations.
<h2>Brokerage Recommendation Trends for ABT</h2>
<img alt="Broker Rating Breakdown Chart for ABT" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABT_09052024.png" style="width:100%" title="" /> 
The ABR suggests buying Abbott, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every &quot;Strong Sell&quot; recommendation, brokerage firms assign five &quot;Strong Buy&quot; recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock&#39;s future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock&#39;s price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
<h2>Zacks Rank Should Not Be Confused With ABR</h2>
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers&#39; vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company&#39;s changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
<h2>Is ABT a Good Investment?</h2>
In terms of earnings estimate revisions for Abbott, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.66.
Analysts&#39; steady views regarding the company&#39;s earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Abbott.
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Abbott.
<a href="https://www.zacks.com/stock/news/2332013/is-it-worth-investing-in-abbott-abt-based-on-wall-street-s-bullish-views?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2332013">To read this article on Zacks.com click here.</a>

Earnings

Is It Worth Investing in Abbott Based on Wall Street's Bullish Views?

<ul>
<li>Designed for people interested in improving their overall health and wellness</li>
<li>Provides real-time glucose data and personal coaching insights based on the body's reaction to nutrition, exercise and life's daily stressors</li>
<li>Available without a prescription;</li>
</ul>

Abbott's Lingo Continuous Glucose Monitor Now Available In U.S.

Abbott Laboratories (ABT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry Biegels...

Buy Rating on Abbott Laboratories: Swift Clinical Advances and Strategic International Expansion

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

Dividend Champion, Contender, And Challenger Highlights: Week Of October 13

Wall Street Breakfast: The Week Ahead

Earnings week ahead: BAC, GS, JNJ, TSM, UNH, ABT, UAL, NFLX, PG, AXP and more

This week, several major companies will be reporting earnings. Among them are Netflix (NFLX), Bank of America (BAC), Johnson & Johnson (JNJ), Citig...

Options Volatility and Implied Earnings Moves This Week, October 15 – October 18, 2024

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

7 out of 8 S&P 500 companies deliver EPS wins this week - Earnings scorecard

Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.

Healthcare Sector Update: Life In The Slow Lane While We Wait For Biotech Bounce

IYH: Healthcare Dashboard For October

ABBV

ADBE

ALKS

ALLY

AMGN

AROW

ASML

AVNT

BANF

BLNK

BYDDF

CAPR

CHCO

CINF

COLL

CSWI

CTRE

CTRI

CUBE

CYTK

ERIC

EXEL

FITB

FLIC

FMAO

FNLC

FUNC

GAIN

GEHC

GSBC

GWRS

HBAN

HBNC

HRMY

IBKR

IBTA

IIPR

INFY

INTC

INTU

INVA

INVH

IRDM

IROQ

ISRG

JBHT

KARO

LECO

LNVGY

MGRC

MIRM

MPWR

MSFT

MTEN

NAPA

NFLX

NRBO

NVNO

NWFL

OCGN

OKTA

QCOM

RBCAA

REGN

REXR

RGCO

RGLD

RSPH

SCVL

SCYX

SERV

SFHG

SRRK

STAG

STLD

TFII

THFF

TSLA

TYBT

TYCB

ULTA

USGO

VANI

VLKAF

VRSSF

WDFC

YORW

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

Abbott's AVEIR™ DR - World's First Dual Chamber Leadless Pacemaker System - Now Available in Canada

Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S.

Dividends

Abbott Declares 403rd Consecutive Quarterly Dividend

Abbott Hosts Conference Call for Third-Quarter Earnings

Abbott and the Big Ten Conference Tackle U.S. Blood Shortages with First-of-its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive'

Comments

Abbott Laboratories

Noticias

Últimas noticias sobre Abbott Laboratories (NYSE:ABT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL